Lupus

The addition of dapirolizumab pegol to standard therapy may warrant further investigation for the treatment of systemic lupus erythematosus, phase 2 trial results suggest.

Adding the calcineurin inhibitor voclosporin to background immunosuppressive therapy improves renal response rates among people with lupus nephritis, show phase 3 trial results published in The Lancet.

A French nationwide study has described COVID-19 outcomes in patients with systemic lupus erythematosus.

An external validation study suggests that the novel Systemic Lupus International Collaborating Clinics frailty index predicts organ damage accrual and mortality risk in patients with longstanding systemic lupus erythematosus.

Preliminary study results from the COVID-19 Global Rheumatology Alliance suggest that pregnant women with rheumatic and musculoskeletal diseases have generally favorable outcomes following SARS-CoV-2 infection.

Both systemic lupus erythematosus and rheumatoid arthritis are associated with an increased risk for symptomatic cardiovascular events but data are lacking for asymptomatic events, results of a systematic review and meta-analysis show.